They found that the plasma Lp-PLA2 level in AD patients was significantly increased, and the use of Lp-PLA2 inhibitors can reduce the deposition of β-amyloid protein, thereby alleviating the symptoms of AD patients. This evidence concerns the gene PLA2G7 and Alzheimer disease.